Updating results

Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413

In development [GID-TA10329] Expected publication date: TBC

Technology appraisal guidance In development

Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Technology appraisal guidance In development

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Technology appraisal guidance In development

Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated endometrial cancer [ID1205]

In development [GID-TA10243] Expected publication date: TBC

Technology appraisal guidance In development

Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Technology appraisal guidance In development

Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Technology appraisal guidance In development

Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

In development [GID-TA10121] Expected publication date: TBC

Technology appraisal guidance In development

Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-positive breast cancer [ID1412]

In development [GID-TA10398] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 09 December 2020

NICE guideline In development

Lurbinectidin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Technology appraisal guidance In development

Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]

In development [GID-TA10149] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]

In development [GID-TAG410] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile associated diarrhoea - tolevamer [ID378]

In development [GID-TAG389] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]

In development [GID-TAG405] Expected publication date: TBC

Technology appraisal guidance In development

Cardiac transplantation (rejection) - everolimus [ID114]

In development [GID-TAG232] Expected publication date: TBC

Technology appraisal guidance In development

Heart failure (acute decompensated) - nesiritide [ID384]

In development [GID-TAG376] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - idraparinux sodium [ID375]

In development [GID-TAG383] Expected publication date: TBC

Technology appraisal guidance In development

Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

In development [GID-TAG384] Expected publication date: TBC

Technology appraisal guidance In development

Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

In development [GID-TAG385] Expected publication date: TBC

Technology appraisal guidance In development

Diabetic retinopathy - ruboxistaurin [ID382]

In development [GID-TAG386] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

In development [GID-TAG388] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]

In development [GID-TAG391] Expected publication date: TBC

Technology appraisal guidance In development

Juvenile idiopathic arthritis - adalimumab [ID385]

In development [GID-TAG400] Expected publication date: TBC

Technology appraisal guidance In development

Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]

In development [GID-TAG416] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]

In development [GID-TAG408] Expected publication date: 01 May 2011

Technology appraisal guidance In development

Pancreatic cancer - capecitabine [ID389]

In development [GID-TAG394] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (advanced and metastatic) - temozolomide [ID316]

In development [GID-TAG401] Expected publication date: TBC

Technology appraisal guidance In development

Nintedanib for previously treated metastatic colorectal cancer [ID1030]

In development [GID-TA10138] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

In development [GID-TA10140] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

In development [GID-TA10144] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

In development [GID-TAG406] Expected publication date: TBC

Technology appraisal guidance In development

NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)

In development [GID-TA10183] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for treating recurrent glioblastoma [ID998]

In development [GID-TA10126] Expected publication date: TBC

Technology appraisal guidance In development

ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Technology appraisal guidance In development

Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Technology appraisal guidance In development

Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

NICE guideline In development

Guadecitabine for untreated acute myeloid leukaemia ID1411

In development [GID-TA10325] Expected publication date: TBC

Technology appraisal guidance In development

Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Technology appraisal guidance In development

PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Technology appraisal guidance In development

Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Technology appraisal guidance In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Technology appraisal guidance In development